> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Perceptive Advisors Sold 5.5 Million Nautilus Shares And Slips Below A 5% Stake
- URL: https://www.bullished.co/perceptive-advisors-sold-5-5-million-nautilus-shares-and-slips-below-a-5-stake-3fd93416/
- Published: 2026-11-03T21:16:42.000Z
- Updated: 2026-11-03T21:16:42.000Z
- Description: Joseph Edelman's fund manager now holds 3.9% of Nautilus Biotechnology after open-market sales that ran from July 28 to October 26.
- Author: Matteo Parrino
- Tags: SEC Filings, NAUT, Industry: Healthcare, Topic: Ownership & Activism

Perceptive Advisors, the investment manager run by Joseph Edelman, [sold 5,538,839 shares](https://www.sec.gov/Archives/edgar/data/1224962/000119312526445289/acrv-ex99%5F1.htm?ref=bullished.co) of [Nautilus Biotechnology](https://www.bullished.co/tag/naut/) in 16 transactions between July 28 and October 26 and now holds [4,944,512 shares, or 3.9%](https://www.sec.gov/Archives/edgar/data/0001224962/000119312526445289/xslSCHEDULE%5F13D%5FX01/primary%5Fdoc.xml?ref=bullished.co) of the company. An amendment to its ownership filing, filed Tuesday, says it ceased on October 16 to own more than five percent of the common stock.

## Sales through a October rally

All the sales were made in the open market through brokers, the filing said. They were made by Perceptive Life Sciences Master Fund, and the schedule lists 16 trade dates, not consecutive trading days.

The largest single-day sale was 885,976 shares on October 12 at a weighted average price of $2.0136\. The highest average price was $3.1154, for 170,000 shares on October 23, and the last sale, 250,000 shares on October 26, went at $2.3604.

The first entry, on July 28, was a short sale of 1,933 shares at $1.3081\. The heavy selling began September 29 at $1.5000 a share.

## Who holds what now

Perceptive Life Sciences Master Fund directly holds 4,778,652 shares, or 3.8% of the class. C2 Life Sciences holds 165,860 shares, or 0.1%. Perceptive Advisors, which manages both vehicles, and Edelman, its managing member, hold no shares directly but share voting power over all 4,944,512.

The percentages rest on 127,372,425 shares outstanding as of October 22, as reported in Nautilus's quarterly report filed October 27.

## The company being sold

Nautilus Biotechnology is a development-stage life sciences company building a platform to measure proteins. Its Voyager platform pairs instruments, consumables and software to analyze single protein molecules. The company launched an Early Access Program in January 2026, offering select customers a Tau Proteoforms assay through its fee-for-service analysis services, and plans to sell the platform later.

Its market value was about $297 million at the time of Tuesday's report.

Dropping below five percent ends the sixth-amendment-long run of required activist-style reporting at the old threshold for Perceptive's Nautilus position.

Learn

- [13D Filing Requirements And Deadline, Shown With Real Filings →](https://www.bullished.co/learn/13d-filing-requirements/)  
A Schedule 13D is required when you own more than 5% of a public company's voting shares. See the deadline, contents and real filings from this week.
- [13D Vs 13G: What Each 5% Stake Filing Means And How To Read One →](https://www.bullished.co/learn/13d-vs-13g/)  
13D vs 13G: both report stakes above 5%, but 13G is the short passive form and 13D explains intent. See real BlackRock and Pictet filings read in plain English.

### Sources

- [SCHEDULE 13D/A — Perceptive Advisors LLC re: Nautilus Biotechnology, Inc. (NAUT)](https://www.sec.gov/Archives/edgar/data/0001224962/000119312526445289/xslSCHEDULE%5F13D%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [SCHEDULE 13D/A Exhibit 99.1](https://www.sec.gov/Archives/edgar/data/1224962/000119312526445289/acrv-ex99%5F1.htm?ref=bullished.co) — SEC EDGAR

### More on Nautilus Biotechnology

- [Nautilus Eyes A Capital Raise By Mid-2027 As CEO Pitches Proteoforms, Not Gene Count, As The Key To Biology](https://www.bullished.co/nautilus-eyes-a-capital-raise-by-mid-2027-as-ceo-pitches-proteoforms-not-gene-count-as-the-281d71fe/)
- [Nautilus Eyes A Fundraise Before Mid-2027, Though Cash Lasts Into 2028](https://www.bullished.co/nautilus-eyes-a-fundraise-before-mid-2027-though-cash-lasts-into-2028-b929f5d2/)
- [Nautilus Biotechnology Lines Up A $125 Million Stock-Sale Program With $114.3 Million In Cash Left](https://www.bullished.co/nautilus-biotechnology-lines-up-a-125-million-stock-sale-program-with-114-3-million-in-3e6bebd4/)

[All Nautilus Biotechnology (NAUT) coverage →](https://www.bullished.co/tag/naut/)